Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Summary not available.
Summary not available.
Summary not available.
Castle Biosciences (NASDAQ: CSTL) has presented new data at the 19th European Association of Dermato-Oncology Congress in Rome, highlighting the effectiveness of its DecisionDx®-Melanoma test for patients with stage I cutaneous melanoma (CM). This innovative test enhances risk stratification compared to the traditional AJCC staging, which relies solely on clinical and pathologic factors. Specifically, DecisionDx-Melanoma shows improved recurrence-free survival (RFS) rates of 97.3% for low-risk Class 1A compared to 77.3% for high-risk Class 2B. Additionally, it demonstrates better melanoma-specific survival (MSS) with rates of 98.0% for Class 1A versus 92.3% for Class 2B. Notably, high-risk patients identified by the test were 5.4 times more likely to die from melanoma compared to AJCC-staged patients, indicating the potential of DecisionDx-Melanoma in guiding enhanced clinical care.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced new findings from a patient simulation study to be presented at ESGE Days 2023. The study indicated that the TissueCypher® Barrett’s Esophagus test significantly enhances management decisions for patients with low-grade dysplasia (LGD) in Barrett’s esophagus (BE). Results showed that the likelihood of appropriate treatment increased from 9% with pathology alone to 77.3% when using TissueCypher results. This test may help reduce both unnecessary endoscopies for low-risk patients and improve outcomes for high-risk patients. The presentation will occur on April 22 in Dublin, Ireland, highlighting the potential of TissueCypher to standardize treatment and reduce the risk of advancing to esophageal cancer.
Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for the first quarter ended March 31, 2023, on May 3, 2023, after market close. Management will conduct a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results. Interested parties can access the live webcast through the Company's Investor Relations page, with a replay available afterward. Castle Biosciences provides innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions, and is progressing with R&D for other high-need diseases, including therapies for psoriasis and atopic dermatitis.
Castle Biosciences, Inc. (Nasdaq: CSTL) has announced that CEO Derek Maetzold and CFO Frank Stokes will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 4:30 p.m. Eastern time.
The presentation will be accessible through a live audio webcast on Castle Biosciences' website, with a replay available post-event.
Castle Biosciences is focused on innovative diagnostic tests that guide patient care, primarily in skin and mental health conditions. Its portfolio includes tests for skin cancers and Barrett’s esophagus, with ongoing research for new diagnostics in high-need areas like psoriasis and atopic dermatitis.
Castle Biosciences, Inc. (NASDAQ: CSTL) has released new data on its DecisionDx-SCC test, demonstrating significant improvements in predicting metastatic risk for cutaneous squamous cell carcinoma (cSCC) patients with risk factors. Conducted on a cohort of 534 patients from 45 centers, the study showed that the DecisionDx-SCC test enhances the predictive accuracy of existing staging systems (AJCC8 and BWH). Notably, the incorporation of the DecisionDx-SCC results improved the likelihood ratios for metastatic risk predictions (p0.0003). This reflects a critical advancement in guiding risk-aligned patient care for high-risk cSCC patients.
Castle Biosciences (Nasdaq: CSTL), a diagnostics company focusing on innovative health solutions, has announced that Derek Maetzold and Frank Stokes will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum. The event is scheduled for March 22, 2023, at 2:15 p.m. Eastern time. Interested parties can access a live audio webcast on Castle Biosciences’ website, with a replay available later. Castle is advancing diagnostics for conditions including skin cancers and mental health and is developing tests for various diseases.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced the showcasing of new data on its skin cancer gene expression profile (GEP) tests at the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans. The company emphasizes the importance of these tests in guiding clinical decisions and improving patient outcomes. Highlights include a late-breaking oral presentation on the 40-gene expression profile for cutaneous squamous cell carcinoma and three ePosters focusing on their DecisionDx tests for melanoma and SCC. These findings underpin Castle's commitment to advancing patient care through evidence-based innovation.